72 Automatic Dispersing System for Particle Analysis in Suspensions and Emulsions
Fritsch’s proven particle sizer ANALYSETTE 28 ImageSizer in combination with the new automatic and powerful wet dispersion is especially suitable for fine particles, poorly free-flowing, fine-agglomerating or sticky materials that do not react in water or other liquids.
For perfect dispersion, the sample material is placed in a closed liquid circuit and pumped through the measuring cell between the camera and the LED stroboscope light at high pump power. The continuously recorded images form the basis for the analysis with a variety of evaluation options.
For wet measurement, choose from 3 different bi-telecentric objectives for optimum adaptation of the total measuring range from 5 µm to 3 mm to your measuring task. In combination with the powerful industrial camera, they guarantee the highest accuracy of the imaging of each individual particle always at the same imaging scale and the highest shape accuracy with the greatest possible depth of field.
The fully automatic wet dispersion unit has no valves and moving seals in the sample circuit for emptying the system. This makes it significantly more robust and virtually wear-free. There are no hard-to-clean dead spaces in which dirt can become permanently lodged. A single rinse is all it takes and it is ready for use again.
For samples that tend to agglomerate, a powerful ultrasonic box can Be connected to the wet dispersion unit. It enables an even finer adjustment of the wet dispersion to the respective sample.
A powerful centrifugal pump with individually adjustable speed ensures optimal transport of even heavy, high- density particles in the wet dispersion unit enabling fast, uniform distribution of the sample material in the entire circuit. With SOP’s for easy operation, a completely free programmable dispersion process and automatic cleaning, fast and reproducible measuring results are ensured.
For measurement results, the modern evaluation software ISS clearly shows each captured particle as a data point in the immediately available Fritsch Cloud as well as in the Fritsch Gallery. You can analyse and evaluate individual selected particles at any time with all available size and shape parameters or get an overview of the typical particle shape of the examined sample.
More information online:
ilmt.co/PL/mJB6 55138pr@reply-direct.com High Quality Autoclaves for a Wide Range of Applications
SMS, headquartered in Poland, has been a reputable manufacturer of sterilisers since 1946. The company’s AS and ASL Series of laboratory autoclaves are designed to provide high quality repeatable performance and accountability for a wide range of applications used in research institutes, universities, medical, pharmaceutical, biotechnology, food and chemical industries, which include: liquid sterilisation, agar preparation, pipette and glass sterilisation, instrument sterilisation (wrapped or unwrapped), biohazard and waste sterilisation and specialised customised cycles.
SMS are driven by passion for quality, both for their products and services. Many customers have recognised the attention to detail, from R&D to manufacturing and through the whole product lifecycle. This has made SMS a leading producer not only in Poland but also worldwide.
SMS has a proven track record of being a highly reliable partner. The company believes in long-term relationships with partners supplying them with the best quality products, competitive prices and a high level of service and support. This enables authorised partners to focus on growing their business with the confidence of having a trustworthy installed base.
More information online:
ilmt.co/PL/Xjyy 55103pr@reply-direct.com World Renowned Affinity-Purified Anti-HIV-1 gp120 Antibody Relaunched
Aalto Bio Reagents is delighted to announce the re-launch of their world renowned affinity-purified anti-HIV-1 gp120 antibody, code D7324, for research use globally. Aalto Bio Reagents has been supplying HIV reagents to the research community since 1988 and there are now over 100 international cited publications referencing use of our HIV-1 gp120. Produced by immunising sheep with the gp120 protein sequence of the BH-10 strain, this antibody targets the most dominant subtype of HIV-1 seen in the Americas, Western Europe and Australasia - subtype B.
Since the first reported cases in 1981, HIV continues to be a major public health issue with over 38 million people living with the infection worldwide, 7 million of whom are unaware they have the infection. Although there are successful treatments now available for managing HIV, there are still consistently large numbers of people becoming newly infected, with almost 2 million adults and over 150,000 children becoming infected with the virus each year. This indicates just how essential the development of a vaccine is for the establishment of long-term control of the virus. According to UNAIDS, it is estimated that a vaccine with just 50% effectiveness could have a major impact on the epidemic and would also dramatically cut the costs associated with the current treatment - lifelong antiretroviral therapy. Vaccine development efforts are focused on the HIV-1 envelope glycoprotein (Env), a trimer consisting of three gp120 and gp41 subunits. However, further research is needed here, as the major problem for vaccine development is the intrinsic metastability of this Env which is necessary for its membrane fusion.
More information online:
ilmt.co/PL/n5Er 54611pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188 |
Page 189 |
Page 190 |
Page 191 |
Page 192 |
Page 193 |
Page 194 |
Page 195 |
Page 196
